Literature DB >> 33923983

The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma.

Arantxa Carrasco-León1,2, Ane Amundarain1,2, Nahia Gómez-Echarte1,2, Felipe Prósper1,2,3, Xabier Agirre1,2.   

Abstract

MM is a hematological neoplasm that is still considered an incurable disease. Besides established genetic alterations, recent studies have shown that MM pathogenesis is also characterized by epigenetic aberrations, such as the gain of de novo active chromatin marks in promoter and enhancer regions and extensive DNA hypomethylation of intergenic regions, highlighting the relevance of these non-coding genomic regions. A recent study described how long non-coding RNAs (lncRNAs) correspond to 82% of the MM transcriptome and an increasing number of studies have demonstrated the importance of deregulation of lncRNAs in MM. In this review we focus on the deregulated lncRNAs in MM, including their biological or functional mechanisms, their role as biomarkers to improve the prognosis and monitoring of MM patients, and their participation in drug resistance. Furthermore, we also discuss the evidence supporting the role of lncRNAs as therapeutic targets through different novel RNA-based strategies.

Entities:  

Keywords:  RNA-based therapy; lncRNAs; multiple myeloma

Year:  2021        PMID: 33923983     DOI: 10.3390/cancers13081976

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.

Authors:  Yung-Hung Luo; Yi-Ping Yang; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Afeez Adekunle Ishola; Yueh Chien; Yuh-Min Chen; Ping-Hsing Tsai; Tzu-Wei Lin; Mong-Lien Wang; Shih-Hwa Chiou
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

2.  Targeting the lncRNA DUXAP8/miR-29a/PIK3CA Network Restores Doxorubicin Chemosensitivity via PI3K-AKT-mTOR Signaling and Synergizes With Inotuzumab Ozogamicin in Chemotherapy-Resistant B-Cell Acute Lymphoblastic Leukemia.

Authors:  Li Zhang; Shixia Zhou; Tiejun Zhou; Xiaoming Li; Junling Tang
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

Review 3.  Therapeutic Approaches for Age-Related Macular Degeneration.

Authors:  Ruth M Galindo-Camacho; Cristina Blanco-Llamero; Raquel da Ana; Mayra A Fuertes; Francisco J Señoráns; Amélia M Silva; María L García; Eliana B Souto
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.